Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Proc Natl Acad Sci U S A ; 120(2): e2211977120, 2023 01 10.
Artigo em Inglês | MEDLINE | ID: mdl-36595694

RESUMO

Engineered microbes for the delivery of biologics are a promising avenue for the treatment of various conditions such as chronic inflammatory disorders and metabolic disease. In this study, we developed a genetically engineered probiotic delivery system that delivers a peptide to the intestinal tract with high efficacy. We constructed an inducible system in the probiotic Lactobacillus reuteri to secrete the Kv1.3 potassium blocker ShK-235 (LrS235). We show that LrS235 culture supernatants block Kv1.3 currents and preferentially inhibit human T effector memory (TEM) lymphocyte proliferation in vitro. A single oral gavage of healthy rats with LrS235 resulted in sufficient functional ShK-235 in the circulation to reduce inflammation in a delayed-type hypersensitivity model of atopic dermatitis mediated by TEM cells. Furthermore, the daily oral gavage of LrS235 dramatically reduced clinical signs of disease and joint inflammation in rats with a model of rheumatoid arthritis without eliciting immunogenicity against ShK-235. This work demonstrates the efficacy of using the probiotic L. reuteri as a novel oral delivery platform for the peptide ShK-235 and provides an efficacious strategy to deliver other biologics with great translational potential.


Assuntos
Artrite Reumatoide , Probióticos , Ratos , Humanos , Animais , Canal de Potássio Kv1.3/genética , Canal de Potássio Kv1.3/metabolismo , Peptídeos/metabolismo , Artrite Reumatoide/tratamento farmacológico , Inflamação/tratamento farmacológico , Probióticos/uso terapêutico , Bloqueadores dos Canais de Potássio/farmacologia , Bloqueadores dos Canais de Potássio/uso terapêutico
2.
Mol Syst Biol ; 13(4): 923, 2017 04 03.
Artigo em Inglês | MEDLINE | ID: mdl-28373240

RESUMO

There is a groundswell of interest in using genetically engineered sensor bacteria to study gut microbiota pathways, and diagnose or treat associated diseases. Here, we computationally identify the first biological thiosulfate sensor and an improved tetrathionate sensor, both two-component systems from marine Shewanella species, and validate them in laboratory Escherichia coli Then, we port these sensors into a gut-adapted probiotic E. coli strain, and develop a method based upon oral gavage and flow cytometry of colon and fecal samples to demonstrate that colon inflammation (colitis) activates the thiosulfate sensor in mice harboring native gut microbiota. Our thiosulfate sensor may have applications in bacterial diagnostics or therapeutics. Finally, our approach can be replicated for a wide range of bacterial sensors and should thus enable a new class of minimally invasive studies of gut microbiota pathways.


Assuntos
Proteínas de Bactérias/metabolismo , Colite/microbiologia , Ácido Tetratiônico/análise , Tiossulfatos/análise , Animais , Técnicas Biossensoriais , Colite/induzido quimicamente , Colite/diagnóstico , Colo/microbiologia , Modelos Animais de Doenças , Fezes/microbiologia , Microbioma Gastrointestinal , Camundongos , Shewanella/metabolismo , Dodecilsulfato de Sódio/efeitos adversos , Biologia de Sistemas/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA